Data fails to support routine use of doxorubicin and ifosfamide combination for soft tissue sarcoma
In the oncology community, it is common knowledge that sarcomas are rare tumours. Indeed, their overall incidence is approximately five per 100,000 people every year, making the feasibility of conducting statistically powered clinical trials a significant challenge. Adding to this is the fact that sarcomas are made up of several different histological types, so conducting a clinical trial in one specific histological type of sarcoma is virtually impossible!